Annexin II tetramer inhibits plasmin-dependent fibrinolysis. 1998

K S Choi, and J Ghuman, and G Kassam, and H M Kang, and S L Fitzpatrick, and D M Waisman
Cancer Biology Research Group, Department of Medical Biochemistry, University of Calgary, Calgary, Alberta, Canada T2N 4N1.

In this paper, we have characterized the regulation of plasmin activity by annexin II tetramer (AIIt). Plasmin activity was measured by a fibrin lysis assay in which a fibrin polymer was produced from purified components and the extent of polymer lysis was determined by following changes in turbidity. Extrinsic lysis of the fibrin polymer, initiated by addition of tissue plasminogen activator (t-PA), was totally blocked if AIIt was present during fibrin polymer formation. Furthermore, fibrin polymer formed in the presence of AIIt was resistant to extrinsic lysis initiated by addition of plasmin. AIIt bound to fibrin polymer under conditions in which polymer lysis was inhibited. Plasmin-dependent extrinsic lysis of the fibrin polymer was also blocked if AIIt was present in the incubation medium, and under these conditions the amidolytic activity of plasmin, measured with an artificial substrate, was inhibited about 5-fold. In contrast, in the absence of fibrin, and at an AIIt/plasmin molar ratio of 526, the amidolytic activity of plasmin was inhibited by only 22.3% +/- 7.4% (mean +/- SD, n = 5) by AIIt. Plasmin-dependent fibrinolysis was only slightly inhibited if fibrin polymer was formed in the presence of annexins I, II, V, or VI. These results identify AIIt as an in vitro regulator of plasmin activity.

UI MeSH Term Description Entries
D010959 Tissue Plasminogen Activator A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases. Alteplase,Plasminogen Activator, Tissue-Type,T-Plasminogen Activator,Tissue-Type Plasminogen Activator,Actilyse,Activase,Lysatec rt-PA,TTPA,Tisokinase,Tissue Activator D-44,Lysatec rt PA,Lysatec rtPA,Plasminogen Activator, Tissue,Plasminogen Activator, Tissue Type,T Plasminogen Activator,Tissue Activator D 44,Tissue Type Plasminogen Activator
D002135 Calcium-Binding Proteins Proteins to which calcium ions are bound. They can act as transport proteins, regulator proteins, or activator proteins. They typically contain EF HAND MOTIFS. Calcium Binding Protein,Calcium-Binding Protein,Calcium Binding Proteins,Binding Protein, Calcium,Binding Proteins, Calcium,Protein, Calcium Binding,Protein, Calcium-Binding
D005341 Fibrinolysin A product of the lysis of plasminogen (profibrinolysin) by PLASMINOGEN activators. It is composed of two polypeptide chains, light (B) and heavy (A), with a molecular weight of 75,000. It is the major proteolytic enzyme involved in blood clot retraction or the lysis of fibrin and quickly inactivated by antiplasmins. Plasmin,Fibrogammin,Glu-Plasmin,Protease F,Thrombolysin,Glu Plasmin
D005342 Fibrinolysis The natural enzymatic dissolution of FIBRIN. Fibrinolyses
D006868 Hydrolysis The process of cleaving a chemical compound by the addition of a molecule of water.
D000577 Amides Organic compounds containing the -CO-NH2 radical. Amides are derived from acids by replacement of -OH by -NH2 or from ammonia by the replacement of H by an acyl group. (From Grant & Hackh's Chemical Dictionary, 5th ed) Amide
D000933 Antifibrinolytic Agents Agents that prevent fibrinolysis or lysis of a blood clot or thrombus. Several endogenous antiplasmins are known. The drugs are used to control massive hemorrhage and in other coagulation disorders. Antifibrinolysin,Antifibrinolysins,Antifibrinolytic,Antifibrinolytic Agent,Antiplasmin,Antiplasmins,Antifibrinolytics,Plasmin Inhibitor,Plasmin Inhibitors,Agent, Antifibrinolytic,Agents, Antifibrinolytic,Inhibitor, Plasmin,Inhibitors, Plasmin
D015842 Serine Proteinase Inhibitors Exogenous or endogenous compounds which inhibit SERINE ENDOPEPTIDASES. Serine Endopeptidase Inhibitor,Serine Endopeptidase Inhibitors,Serine Protease Inhibitor,Serine Protease Inhibitors,Serine Proteinase Antagonist,Serine Proteinase Antagonists,Serine Proteinase Inhibitor,Serine Proteinase Inhibitors, Endogenous,Serine Proteinase Inhibitors, Exogenous,Serine Protease Inhibitors, Endogenous,Serine Protease Inhibitors, Exogenous,Antagonist, Serine Proteinase,Endopeptidase Inhibitor, Serine,Inhibitor, Serine Endopeptidase,Inhibitor, Serine Protease,Inhibitor, Serine Proteinase,Protease Inhibitor, Serine,Proteinase Antagonist, Serine,Proteinase Inhibitor, Serine
D017306 Annexin A2 A member of the annexin family that is a substrate for a tyrosine kinase, ONCOGENE PROTEIN PP60(V-SRC). Annexin A2 occurs as a 36-KDa monomer and in a 90-KDa complex containing two subunits of annexin A2 and two subunits of S100 FAMILY PROTEIN P11. The monomeric form of annexin A2 was formerly referred to as calpactin I heavy chain. Annexin II,Calpactin I,Lipocortin II,Annexin A2, P90 Complex,Annexin II, P36,Annexin II, P90 Complex,Capactin I Heavy Chain,P36 Annexin II

Related Publications

K S Choi, and J Ghuman, and G Kassam, and H M Kang, and S L Fitzpatrick, and D M Waisman
February 2000, Biochemistry,
K S Choi, and J Ghuman, and G Kassam, and H M Kang, and S L Fitzpatrick, and D M Waisman
March 2000, Biochemistry,
K S Choi, and J Ghuman, and G Kassam, and H M Kang, and S L Fitzpatrick, and D M Waisman
January 2002, Methods in molecular biology (Clifton, N.J.),
K S Choi, and J Ghuman, and G Kassam, and H M Kang, and S L Fitzpatrick, and D M Waisman
January 2002, Biochemistry,
K S Choi, and J Ghuman, and G Kassam, and H M Kang, and S L Fitzpatrick, and D M Waisman
January 1995, Molecular and cellular biochemistry,
K S Choi, and J Ghuman, and G Kassam, and H M Kang, and S L Fitzpatrick, and D M Waisman
July 2001, The Journal of biological chemistry,
K S Choi, and J Ghuman, and G Kassam, and H M Kang, and S L Fitzpatrick, and D M Waisman
November 2009, The Journal of clinical investigation,
K S Choi, and J Ghuman, and G Kassam, and H M Kang, and S L Fitzpatrick, and D M Waisman
September 2000, Archives of biochemistry and biophysics,
K S Choi, and J Ghuman, and G Kassam, and H M Kang, and S L Fitzpatrick, and D M Waisman
November 1995, Biochemistry,
K S Choi, and J Ghuman, and G Kassam, and H M Kang, and S L Fitzpatrick, and D M Waisman
January 1999, Trends in cardiovascular medicine,
Copied contents to your clipboard!